Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin  by Alvarez, J.M. et al.
Generalized myalgia and rhabdomyolysis in association with
the hydroxy methylglutaryl coenzyme A reductase inhibitors
(statins) has not been previously described after cardiac opera-
tions. We report a case of severe myalgia and rhabdomyolysis
producing renal failure necessitating hemodialysis and pro-
longed mechanical ventilation.
Clinical summary. A 62-year-old man with unstable angi-
na refractory to intravenous medical therapy was referred for
urgent redo coronary artery bypass graft (CABG) surgery.
Cardiac catheterization revealed a patent left internal thoracic
artery (ITA) graft to the left anterior descending coronary
artery (LAD) and diseased saphenous vein grafts (SVGs) to
the first circumflex marginal (CX1) and posterior descending
coronary artery. The native circulation had 90% stenoses
affecting the LAD, CX, and posterior descending vessels.
Left ventricular function was normal. Coronary risk factors
were current cigarette smoking and hyperlipidemia.
Medications included aspirin (Cardiprin, Reckitt & Coleman)
150 mg daily, simvastatin (Lescol, Sandoz) 10 mg daily, and
atenolol (Noten, Alphafarm) 50 mg.
Anesthesia was achieved with fentanyl tartrate (Fentanyl,
Astra) 1 mg, pancuronium bromide (Pavulon, Organon
Teknika) 8 mg, and intravenous propafol (Diprovan, ICI).
Cardiopulmonary bypass with moderate systemic hypother-
mia to 32°C was established. Antegrade and retrograde blood
cardioplegia was used for myocardial protection. A free right
ITA was grafted onto the posterior descending artery, and the
left radial artery was used to sequentially graft the CX1 and
CX2.
Discontinuation from cardiopulmonary bypass required no
inotropic support. The immediate postoperative course was
associated with a high cardiac output/low systemic vascular
resistance state (cardiac output, 9 L/min; systemic vascular
resistance, 400 dynes · s ·cm5 requiring intravenous norepi-
nephrine (Levophed, Abbott) 2 m g/kg per minute. The postop-
erative chest x-ray film revealed right-sided mid-zone
pneumonia that was treated with intravenous ceftriaxone
(Rocephin, Hoffmann-LaRoche) 2 g daily. Gas exchange how-
ever was satisfactory.
Forty-eight hours after the operation, unheralded oliguria
(30 mL/h) despite a satisfactory cardiac output (6l L/min),
associated with an increase in creatinine (346 mmol/L) and
hyperkalemia (potassium, 6.9 mmol/L) developed. The olig-
uria was unresponsive to intravenous furosemide 80 mg/h
(Lasix, DBL), intravenous dopamine HCl (Dopamine, CSL)
at 3 m g/kg per hour, and intravenous mannitol 20% (Osmitrol,
Baxter) at 10 mL/h. The patient’s creatine kinase (CK) level
increased to 9000 U/L with an MB isoenzyme of 39 U/L.
Hemodialysis was commenced because of continuing hyper-
kalemia and hypercreatininemia (creatine level 558 mmol/L).
Generalized myalgia also developed. Despite satisfactory
gas exchange, the patient could not generate an adequate tidal
volume (100 mL) and required mechanical ventilation. The
CK level peaked on day 4 at 14,746 units/L, returning to nor-
mal by postoperative day 8. The patient required hemodialy-
sis for 4 days and mechanical ventilation for 25 days. He was
discharged home 15 days later. Streptococcus viridans and
coagulase-negative Staphylococcus were the sole micro-
organisms cultured; assays for Legionella pneumophila were
negative.
Discussion. The statins lower low-density lipoprotein levels
and serum total cholesterol and raise high-density lipoprotein
levels by 40%, 30%, and 10% respectively.1 Statin therapy has
proven beneficial in patients after CABG. Aggressive reduc-
tion of serum low-density lipoprotein levels (<2.5 mmol/L)
after CABG will reduce disease progression in SVGs, the
development of new plaques, and the risk of total occlusions
by 31%, 52%, and 37.5%, respectively.2 Currently, 25% of our
patients referred for CABG are receiving statins.
The statins are well tolerated with a low incidence of side
effects. Myopathy occurs in 0.1% to 0.5% of patients.3
Concomitant use of lovastatin with gemfibrozil, niacin, and
cyclosporine A (INN: ciclosporin) increases the relative risk
of myopathy to 5%, 2%, and 28%, respectively.3,4 Impaired
hepatic function can potentially heighten the risk of side
effects by increasing their bio-availability.3,4 Although the
incidence of rhabdomyolysis is rare (0.04%-0.2%), acute
renal failure resulting from rhabdomyolysis and intraoperative
rhabdomyolysis has been documented.4,5 Patients have been
receiving statin therapy for 2 to 16 months when this compli-
cation has occurred, without any apparent trigger.4,5 This
patient had been receiving simvastatin for 7 years with no
adverse effect.
In this case, preoperative and immediate postoperative
renal and hepatic function were within normal limits. The
intitial CK elevation was consistent with harvesting the right
ITA. Significant CK elevation occurred 24 hours after the
operation, peaking at 72 hours. The serum CK rise mirrored
the elevation in serum creatinine, the development of refrac-
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tory oliguria, and the development of generalized myalgia
and respiratory muscle weakness.
No known drug(s) associated with rhabdomyolysis, itself
rare,4 were administered, nor were any metabolic factors pre-
sent that are capable of potentiating this event. When rhab-
domyolysis has been reported in patients undergoing long-
term therapy, no acute causative factor is apparent.3,4
Rosenberg and colleagues,5 however, have documented intra-
operative rhabdomyolysis associated with pravastatin in
cases in which the operation was thought to be the trigger.
Although speculative, 7 years of uneventful simvastatin ther-
apy in this case, together with the report by Rosenberg’s
group, indicates to us that the timing of this complication and
operation were not coincidental.
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MYXOMA OF RIGHT FEMORAL VEIN ORIGIN PRESENTING AS A RIGHT ATRIAL MASS 
WITH SYNCOPE
Paul S. Ramphal, DM, FRCS(Edin),a Howard W. Spencer, FRCS(Edin), FACS,a Derek I. G. Mitchell, MBBS, DM, and 
Charles Denbow, DM, FRCP, FACP, FACC,b Kingston, Jamaica, West Indies
Myxomas are the most common cardiac tumors, accounting
for approximately 50% of such neoplasms. Right-sided tumors
are considerably less common than left-sided tumors (20% vs
80%), and myxomas of extracardiac origin presenting as
intracardiac masses are rare.1-3 A case of myxoma originating
in a previously undescribed site and presenting as a right atrial
mass with syncope is reported.
Clinical summary. A 44-year-old woman was admitted to
the University Hospital of the West Indies in January 1993. She
had been having progressive dyspnea and episodic syncope
over the preceding year. There were no other symptoms. Other
medical problems included maturity-onset diabetes mellitus
controlled with oral hypoglycemic drugs and hypertension
controlled with propranolol 40 mg daily. Physical examination
revealed an obese woman with a blood pressure of 140/80 mm
Hg, a pulse rate of 90 beats/min and a grade 3/6 systolic mur-
mur at the left sternal edge. The liver was palpable 2 cm below
the right costal margin. Results of liver function tests were
within normal limits. Chest radiography showed no abnormal-
ities, and electrocardiography revealed sinus tachycardia.
Echocardiography showed that the right atrium was almost
completely filled by a mobile, homogeneous mass that inter-
mittently occluded the tricuspid orifice and appeared to origi-
nate from the area of the eustachian valve. The diagnosis of a
right atrial myxoma was made and the patient was taken to the
operating theater. 
At median sternotomy, bicaval cannulation could not be
safely accomplished because palpation of the inferior vena
cava (IVC) revealed that the tumor was emerging into the
right atrium (RA) from within that vessel. The right femoral
vein, superior vena cava, and aortic root were cannulated. On
bypass, the right atrium was opened and a club-shaped, glis-
tening, pink mass of firm consistency was noted to be filling
it. The mass was not attached to the RA and in fact represent-
ed the end of a solid cord of tumor that was emerging from
the IVC orifice, and, under tension, could be made to stretch
a further 2 cm into the RA. The point of origin could not be
ascertained and the decision was made to amputate the stalk
of the tumor under cephalad traction, whereupon the stump,
which was approximately 1 cm in diameter, retracted beyond
sight into the IVC. The patient was weaned off bypass
uneventfully and her postoperative course was unremarkable.
Pathologic examination of the mass revealed a 3 · 7-cm
firm, smooth tumor. Histologic examination revealed myxo-
ma, with no features of malignancy.
The patient was kept under close supervision with serial
ultrasound examinations over the next several months,
because recurrence was expected. Examination 6 months after
the operation suggested that the site of origin of the tumor was
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